881668-93-5 Usage
Description
5-methoxyquinolin-3-amine is a chemical compound with the molecular formula C10H10N2O. It is a derivative of quinoline, which is a heterocyclic aromatic organic compound. 5-methoxyquinolin-3-amine has a methoxy group (CH3O-) attached to the 5th position of the quinoline ring, and an amine group (-NH2) attached to the 3rd position. This unique structure endows it with potential biological activities and makes it a promising candidate for pharmaceutical applications.
Uses
Used in Pharmaceutical Industry:
5-methoxyquinolin-3-amine is used as a key intermediate in the synthesis of new drugs for various therapeutic applications. Its unique structure allows for the development of compounds with specific biological activities, making it a valuable asset in drug discovery and design.
Used in Research and Development:
5-methoxyquinolin-3-amine is used as a building block in the synthesis of new organic compounds with potential therapeutic properties. Researchers utilize its chemical reactivity and structural features to create novel molecules that can be further explored for their efficacy and safety in treating various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 881668-93-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,1,6,6 and 8 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 881668-93:
(8*8)+(7*8)+(6*1)+(5*6)+(4*6)+(3*8)+(2*9)+(1*3)=225
225 % 10 = 5
So 881668-93-5 is a valid CAS Registry Number.
881668-93-5Relevant articles and documents
PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS
-
Page/Page column 117-118, (2010/11/28)
Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
